Home / BUSINESS / Sun pharma expects to stabilize India business in FY19

Sun pharma expects to stabilize India business in FY19

Favorable demographics conditions will help the company to ensure reasonable volume growth in India
Sun Pharmaceutical Industries is excepting its India business to stabilise in the current fiscal leading to reasonable volume growth since company has witnessing disruptions in 2017-18 due to Goods and Services Tax (GST) implementation. However, favorable demographics conditions will help the company to ensure reasonable volume growth in India.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Please share this news